Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Am Heart Assoc ; 9(4): e013168, 2020 02 18.
Article in English | MEDLINE | ID: mdl-32063125

ABSTRACT

Background Recurrent hospitalization is prevalent in women with signs and symptoms of ischemia and no obstructive coronary artery disease. We hypothesized that rates of angina hospitalization might have changed over time, given advances in diagnostic and therapeutic approaches. Methods and Results We evaluated 551 women enrolled in the WISE (Women's Ischemia Syndrome Evaluation) study with no obstructive coronary artery disease (CAD) for a follow-up period of 9.1 years. We analyzed angina hospitalization rates using the Kaplan-Meier method. Univariate analysis and multivariable Cox proportional hazard models were developed for prediction of angina hospitalization in women with signs and symptoms of angina and no CAD. A total of 223 women had nonobstructive CAD (>20-50%

Subject(s)
Angina Pectoris/epidemiology , Coronary Stenosis/epidemiology , Myocardial Ischemia/epidemiology , Patient Admission/trends , Women's Health/trends , Aged , Angina Pectoris/diagnosis , Angina Pectoris/physiopathology , Angina Pectoris/therapy , Coronary Stenosis/diagnostic imaging , Coronary Stenosis/physiopathology , Coronary Stenosis/therapy , Female , Heart Disease Risk Factors , Humans , Middle Aged , Myocardial Ischemia/diagnosis , Myocardial Ischemia/physiopathology , Myocardial Ischemia/therapy , Progression-Free Survival , Risk Assessment , Time Factors , United States/epidemiology
2.
Atherosclerosis ; 253: 111-117, 2016 10.
Article in English | MEDLINE | ID: mdl-27596135

ABSTRACT

BACKGROUND AND AIMS: Ischemia stimulates a reparative response resulting in mobilization of circulating progenitor cells (CPCs). We hypothesized that women with chronic myocardial ischemia from coronary microvascular disease (CMD) will mobilize CPCs. METHODS: In 123 women with ischemic symptoms and signs but no obstructive coronary artery disease (CAD) enrolled in the Women's Ischemia Syndrome Evaluation - Coronary Vascular Dysfunction Study (WISE-CVD), we measured coronary flow reserve (CFR) in response to intracoronary adenosine. Peripheral blood CPCs were measured using flow cytometry for expression of CD34, CD133, CXCR4, and VEGFR2. RESULTS: Subjects were 53 ± 11 years, BMI 30 ± 8; 44% hypertensive, 11% diabetic, 23% hyperlipidemic and 7% smokers. Lower CFR correlated inversely with higher levels of hematopoietic-enriched CD34+ (r = -0.23, p = 0.011), CD34+/CD133+ (r = -0.24, p = 0.008), and CD34+/CXCR4+ (r = -0.19, p = 0.036) cells. In multivariable regression analyses, after adjusting for traditional cardiovascular risk factors, lower CFR remained significantly associated with elevated levels of CD34+ (ß -0.18, p = 0.042), CD34+/CD133+ (ß -0.24, p = 0.036), and CD34+/CXCR4+ (ß -0.22, p = 0.050) cells. We found no association between CFR and CD34+/VEGFR2+ cells. CONCLUSIONS: In women with non-obstructive CAD, impaired CFR is associated with higher levels of CPCs, suggesting that chronic myocardial ischemia from CMD stimulates CPC mobilization. The functional significance of elevated CPCs in these subjects requires further investigation as a potential biomarker and treatment target.


Subject(s)
Coronary Artery Disease/blood , Ischemia/blood , Stem Cells/cytology , Aged , Angiography , Biomarkers/blood , Comorbidity , Coronary Circulation , Female , Hematopoietic Stem Cell Mobilization , Humans , Microcirculation , Middle Aged , Myocardial Ischemia/blood , National Heart, Lung, and Blood Institute (U.S.) , Risk Factors , United States , Vascular Diseases/blood , Women's Health
3.
J Am Coll Cardiol ; 63(2): 103-9, 2014 Jan 21.
Article in English | MEDLINE | ID: mdl-24201078

ABSTRACT

Coronary spasm is an important and often overlooked etiology of chest pain. Although coronary spasm, or Prinzmetal's angina, has been thought of as benign, contemporary studies have shown serious associated adverse outcomes, including acute coronary syndrome, arrhythmia, and death. Definitive diagnosis of coronary spasm can at times be difficult, given the transience of symptoms. Numerous agents have been historically described for provocative testing. We provide a review of published data for the role of provocation testing in the diagnosis of coronary spasm.


Subject(s)
Chest Pain/etiology , Coronary Angiography , Coronary Vasospasm/diagnosis , Electrocardiography , Exercise Test/methods , Acetylcholine , Chest Pain/diagnosis , Coronary Vasospasm/complications , Diagnosis, Differential , Humans , Vasodilator Agents
4.
World J Cardiol ; 4(2): 23-30, 2012 Feb 26.
Article in English | MEDLINE | ID: mdl-22379534

ABSTRACT

Heart failure (HF) is a chronic, progressive illness that is highly prevalent in the United States and worldwide. This morbid illness carries a very poor prognosis, and leads to frequent hospitalizations. Repeat hospitalization in HF is both largely burdensome to the patient and the healthcare system, as it is one of the most costly medical diagnoses among Medicare recipients. For years, investigators have strived to determine methods to reduce hospitalization rates of HF patients. Despite such efforts, recent reports indicate that re-hospitalization rates remain persistently high, without any improvement over the past several years and thus, this topic clearly needs aggressive attention. We performed a key-word search of the literature for relevant citations. Published articles, limited to English abstracts indexed primarily in the PubMed database through the year 2011, were reviewed. This article discusses various clinical parameters, serum biomarkers, hemodynamic parameters, and psychosocial factors that have been reviewed in the literature as predictors of re-hospitalization of HF patients. With this information, our hope is that the future holds better risk-stratification models that will allow providers to identify high-risk patients, and better customize effective interventions according to the needs of each individual HF patient.

5.
Obes Surg ; 22(1): 47-51, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21476124

ABSTRACT

BACKGROUND: One of the most concerning and potentially fatal complications of gastric bypass surgery is pulmonary embolism (PE) with published rates exceeding 1%. Although this procedure has been proven effective in reducing the morbidity and mortality of obesity and associated health care costs, it is elective and risk must be minimized. No dosing guidelines exist for pharmacologic prophylaxis in obese patients who are already at increased risk for these events. Although the current ASMBS and Chest guidelines recommend preoperative pharmacologic prophylaxis against thromboembolic events, no standard dosing protocols exist for the obese population. We propose a protocol including immediate pre followed by twice daily postoperative BMI-based dosing of low-molecular-weight heparin (LMWH), along pneumatic compression devices, and early ambulation. METHODS: We retrospectively reviewed the charts of 170 patients who underwent Roux-en-Y gastric bypass surgery between March 2004 and December 2007. The incidence of deep venous thrombosis (DVT) and PE and bleeding complications associated with a BMI-based preoperative dosing protocol of LMWH was determined. RESULTS: All patients received LMWH preoperatively within 1 h of the incision, with doses varying between 30 and 60 mg given subcutaneously. Eleven patients received 30 mg, 145 patients received 40 mg, 9 patients received 50 mg, and 5 patients received 60 mg. None of the patients suffered from clinically significant DVT or PE during the hospital stay or in follow up (>2 years). Five patients (2.9%) were treated with discontinuation of lovenox and blood transfusion for postoperative bleeding. One of those patients returned to the operating room for exploration. CONCLUSIONS: We propose that immediate BMI-based preoperative dosing of LMWH along with postoperative prophylaxis is both safe and effective and should be standard for all patients undergoing Roux-en-Y gastric bypass surgery.


Subject(s)
Gastric Bypass/adverse effects , Heparin, Low-Molecular-Weight/administration & dosage , Obesity, Morbid/surgery , Postoperative Complications/prevention & control , Pulmonary Embolism/prevention & control , Venous Thrombosis/prevention & control , Adult , Body Mass Index , Dose-Response Relationship, Drug , Female , Humans , Male , Obesity, Morbid/complications , Obesity, Morbid/drug therapy , Postoperative Complications/drug therapy , Postoperative Complications/epidemiology , Pulmonary Embolism/drug therapy , Retrospective Studies , Treatment Outcome , Venous Thrombosis/drug therapy , Venous Thrombosis/epidemiology
6.
Heart Fail Rev ; 17(3): 345-53, 2012 May.
Article in English | MEDLINE | ID: mdl-21643964

ABSTRACT

Heart failure is a progressive illness that carries significant morbidity and mortality. This highly prevalent illness leads to frequent, costly hospitalizations with approximately 50% of patients being readmitted within 6 months of initial hospitalization. While rehospitalization has been extensively studied in the past, little progress has been made in terms of reducing readmission rates of heart failure patients in the last decade despite increasing costs with impending resource limitations. We discuss disease-centered, physician-centered, and patient-centered factors that lead to rehospitalization as well as community/resource availability factors that contribute to rehospitalization of patients suffering from chronic heart failure. In addition, predictors of hospitalization and interventions that reduce hospitalization will be critically evaluated. With a complete understanding of heart failure rehospitalization, we hope the future holds more effective ways to prevent heart failure progression and thus rehospitalization, improved risk-stratification models to identify patients high-risk for rehospitalization, and sustained interventions that are customized according to the etiology of the clinical decline of heart failure patients that ultimately results in frequent rehospitalizations.


Subject(s)
Heart Failure , Patient Readmission , Chronic Disease , Heart Failure/therapy , Hospitalization , Humans , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...